DK3456340T3 - Glp-1-receptorantagonist til brug ved behandling af medfødt hyperinsulisme - Google Patents

Glp-1-receptorantagonist til brug ved behandling af medfødt hyperinsulisme Download PDF

Info

Publication number
DK3456340T3
DK3456340T3 DK18201976.0T DK18201976T DK3456340T3 DK 3456340 T3 DK3456340 T3 DK 3456340T3 DK 18201976 T DK18201976 T DK 18201976T DK 3456340 T3 DK3456340 T3 DK 3456340T3
Authority
DK
Denmark
Prior art keywords
hyperinsulism
glp
congenital
treatment
receptor antagonist
Prior art date
Application number
DK18201976.0T
Other languages
English (en)
Inventor
Doris Stoffers
Leon Diva D De
Charles Stanley
Original Assignee
Univ Pennsylvania
Childrens Hospital Of Philadelphia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania, Childrens Hospital Of Philadelphia filed Critical Univ Pennsylvania
Application granted granted Critical
Publication of DK3456340T3 publication Critical patent/DK3456340T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/26Glucagons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
DK18201976.0T 2007-01-08 2008-01-08 Glp-1-receptorantagonist til brug ved behandling af medfødt hyperinsulisme DK3456340T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87903307P 2007-01-08 2007-01-08
EP14171762.9A EP2818181B1 (en) 2007-01-08 2008-01-08 Compositions and medical uses thereof

Publications (1)

Publication Number Publication Date
DK3456340T3 true DK3456340T3 (da) 2022-03-21

Family

ID=39609282

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18201976.0T DK3456340T3 (da) 2007-01-08 2008-01-08 Glp-1-receptorantagonist til brug ved behandling af medfødt hyperinsulisme

Country Status (13)

Country Link
US (6) US9821031B2 (da)
EP (4) EP4049673A1 (da)
CY (1) CY1125273T1 (da)
DK (1) DK3456340T3 (da)
ES (3) ES2710948T3 (da)
HR (1) HRP20220346T3 (da)
HU (1) HUE058307T2 (da)
LT (1) LT3456340T (da)
PL (1) PL3456340T3 (da)
PT (1) PT3456340T (da)
SI (1) SI3456340T1 (da)
TR (1) TR201900959T4 (da)
WO (1) WO2008085982A2 (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE058307T2 (hu) 2007-01-08 2022-07-28 Univ Pennsylvania GLP-1 receptor antagonista veleszületett hiperinzulinizmus kezelésében történõ használatra
EP2817025A2 (en) * 2012-02-08 2014-12-31 Seneb Biosciences, Inc. Treatment of hypoglycemia
RU2016137264A (ru) * 2014-02-21 2018-03-26 МЕДИММЬЮН, ЭлЭлСи Слияния антитела к pcsk9~glp-1 и способы применения
EP3265491A1 (en) 2015-03-03 2018-01-10 Xoma (Us) Llc Treatment of post-prandial hyperinsulinemia and hypoglycemia after bariatric surgery
WO2016191394A1 (en) * 2015-05-22 2016-12-01 The Bot Of The Leland Stanford Junior University Treatment of post-bariatric hypoglycemia with glp-1 antagonists
US10653753B2 (en) 2016-03-04 2020-05-19 Eiger Biopharmaceuticals, Inc. Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives
WO2018094404A1 (en) 2016-11-21 2018-05-24 Eiger Biopharmaceuticals, Inc. Buffered formulations of exendin (9-39)
CN116606367A (zh) * 2022-05-31 2023-08-18 南京盛德瑞尔医药科技有限公司 长效Exendin-9-39及其在低血糖治疗中的应用和作为治疗低血糖的药物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5424286A (en) * 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US20040092443A1 (en) * 1996-08-06 2004-05-13 Yeda Research And Development Co., Ltd Long-acting exendins and exendin agonists
EP1137413B1 (en) * 1998-12-10 2005-02-02 Agouron Pharmaceuticals, Inc. Non-peptide antagonists of glp-1 receptor and methods of use
US6903074B1 (en) 1999-06-04 2005-06-07 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Neuromedin b and somatostatin receptor agonists
SE0004462D0 (sv) * 2000-12-04 2000-12-04 Pharmacia Ab Novel method and use
WO2002066062A2 (en) * 2001-02-01 2002-08-29 Drucker Daniel J Enhancement of glp-2 activity
AU2002257132A1 (en) 2001-04-06 2002-10-21 The Trustees Of The University Of Pennsylvania Erbb interface peptidomimetics and methods of use thereof
CN1162446C (zh) * 2001-05-10 2004-08-18 上海华谊生物技术有限公司 促胰岛素分泌肽衍生物
US7378385B2 (en) 2002-08-08 2008-05-27 University Of Cincinnati Role for GLP-1 to mediate responses to disparate stressors
DE102004043153B4 (de) 2004-09-03 2013-11-21 Philipps-Universität Marburg Erfindung betreffend GLP-1 und Exendin
WO2007139941A2 (en) 2006-05-26 2007-12-06 Amylin Pharmaceuticals, Inc. Composition and methods for treatment of congestive heart failure
HUE058307T2 (hu) 2007-01-08 2022-07-28 Univ Pennsylvania GLP-1 receptor antagonista veleszületett hiperinzulinizmus kezelésében történõ használatra
PL2310042T3 (pl) 2008-07-08 2013-05-31 Novartis Ag Zastosowanie pasyreotydu do leczenia endogennej hipoglikemii hiperinsulinemicznej
ES2705249T3 (es) 2009-06-08 2019-03-22 Amunix Operating Inc Polipéptidos reguladores de glucosa y métodos para su producción y uso
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
WO2016191394A1 (en) 2015-05-22 2016-12-01 The Bot Of The Leland Stanford Junior University Treatment of post-bariatric hypoglycemia with glp-1 antagonists
WO2018094404A1 (en) 2016-11-21 2018-05-24 Eiger Biopharmaceuticals, Inc. Buffered formulations of exendin (9-39)

Also Published As

Publication number Publication date
HUE058307T2 (hu) 2022-07-28
EP2818181B1 (en) 2018-10-24
US20080269130A1 (en) 2008-10-30
PT3456340T (pt) 2022-05-25
ES2499390T3 (es) 2014-09-29
SI3456340T1 (sl) 2022-08-31
EP2120994A2 (en) 2009-11-25
WO2008085982A3 (en) 2008-11-20
EP3456340B1 (en) 2022-02-16
US9616108B2 (en) 2017-04-11
US20240082361A1 (en) 2024-03-14
US10987407B2 (en) 2021-04-27
ES2710948T3 (es) 2019-04-29
US20100190700A1 (en) 2010-07-29
HRP20220346T3 (hr) 2022-09-02
EP4049673A1 (en) 2022-08-31
EP2818181A1 (en) 2014-12-31
US20180050095A1 (en) 2018-02-22
US10188702B2 (en) 2019-01-29
PL3456340T3 (pl) 2022-08-22
LT3456340T (lt) 2022-05-10
US20190336584A1 (en) 2019-11-07
US20210252110A1 (en) 2021-08-19
EP2120994B1 (en) 2014-06-11
US9821031B2 (en) 2017-11-21
ES2908838T3 (es) 2022-05-04
TR201900959T4 (tr) 2019-02-21
CY1125273T1 (el) 2023-06-09
EP3456340A1 (en) 2019-03-20
EP2120994A4 (en) 2011-09-28
WO2008085982A2 (en) 2008-07-17

Similar Documents

Publication Publication Date Title
DK3456340T3 (da) Glp-1-receptorantagonist til brug ved behandling af medfødt hyperinsulisme
ATE509022T1 (de) Nikotin-acetylcholin-rezeptorsubtyp-selektive diazabicycloalkanamide
DK2129654T3 (da) Antagonister af glucagonreceptoren
FR2924330B1 (fr) Implant pour hernie parastomiale
DK3222277T3 (da) Biphenylsulfonamidendothelin- og angiotensin II-receptorantagonist til behandling af glomerulosklerose og IgA-induceret nefropati
DK2086944T3 (da) Fremgangsmåde til fremstilling af difluormethylpyrazolylcarboxylater
DK2220076T3 (da) Inhibitorer af replikationen af humant immundefektvirus
DK1729753T3 (da) Anvendelse af en NMDA-receptor-antagonist til behandling af tinnitus induceret ved kokleær excitotoksicitet
DK2061485T3 (da) EV576-peptider til anvendelse ved behandling af Guillain-Barré-syndrom
ATE481405T1 (de) Thiazolpyrazolopyrimidine als antagonisten des crf1-rezeptors
DK3219815T3 (da) Fremgangsmåder og sammensætninger til at fremstille squalen under anvendelse af gær
FI20070924A0 (fi) Hissin valmiustila
FIU20060061U0 (fi) Kaidejärjestelmä
DK2200600T3 (da) Neramexan til anvendelse ved behandlingen af subakut tinnitus
DK2124946T3 (da) Anvendelse af N-methylpyridiniumderivater til hepatobeskyttelse
DE112008002921A5 (de) Bohrfutter
ZA200808766B (en) Nitrated heterocyclic compounds as endothelin receptor antagonist
DK1856035T3 (da) Fremgangsmåde til fremstilling af beskyttelse amidiner
DK2121138T3 (da) Terapeutiske anvendelser af eslicarbazepin
DK2120919T3 (da) Ny kombination til anvendelse ved behandling af inflammatoriske lidelser
ITRA20060017U1 (it) Gruppo erogatore per lavelli
GB0714649D0 (en) Novel viral replication inhibitors
DK2621517T4 (da) Sammensætning til anvendelse i behandlingen af infertilitet
DK1992352T3 (da) Middel til anvendelse i forbyggelsen af aterosklerosis
DK2001499T3 (da) Anvendelse af TGS-6 til behandling af osteoporose